Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;120(3):570-575.
doi: 10.14309/ajg.0000000000002953. Epub 2024 Jul 17.

The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints

Affiliations

The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints

Elliot B Tapper et al. Am J Gastroenterol. .

Abstract

Introduction: One of the primary goals of the Liver Cirrhosis Network (LCN) is to develop a cohort study to better understand and predict the risk of hepatic decompensation and other clinical and patient-reported outcomes among patients with Child A cirrhosis.

Methods: The LCN consists of a Scientific Data Coordinating Center and 10 clinical centers whose investigators populate multiple committees. The LCN Definitions and Measurements Committee developed preliminary definitions of cirrhosis and its complications by literature review, expert opinion, and reviewing definition documents developed by other organizations. The Cohort Committee developed the study protocol with the input of the steering committee.

Results: The LCN developed a prospective cohort study to describe and predict the rates of incident clinical events pertaining to first decompensation and patient-reported outcomes. The LCN developed a pragmatic definition of compensated cirrhosis incorporating clinical, laboratory, imaging, and histological criteria. Definitions of incident and recompensated ascites, overt hepatic encephalopathy, variceal hemorrhage, bleeding because of portal gastropathy, and hepatocellular carcinoma were also codified.

Discussion: The LCN Cohort Study design will inform the natural history of cirrhosis in contemporary patients with compensated cirrhosis. The LCN Definitions and Measures Committee developed criteria for the definition of cirrhosis to standardize entry into this multicenter cohort study and standardized criteria for liver-related outcome measures. This effort has produced definitions intended to be both sensitive and specific as well as easily operationalized by study staff such that outcomes critical to the LCN cohort are identified and reported in an accurate and generalizable fashion.

Registration: NCT05740358.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest:

Tapper has consulted for Bausch, Mallinckrodt, Axcella, Novo Nordisk, Ambys, Lipocine, Kaleido, Takeda.

Bajaj has consulted for Merz and Norgine and his institution has received funding from Bausch, Grifols, Axcella, Mallinckrodt and Cosmo.

Goldberg: Research grant support paid to my institution from Gilead and AbbVie

Brown: consulted for Bausch, Mallinckrodt, Ambys, Intercept, Antios, Gilead, Abbvie, Takeda

Verna: grant support to institution from Salix

Terrault: Institutional grant support from GSK, Gilead, Roche-Genentech, Helio Health, DURECT Corp, Eiger Pharmaceuticals.

Hameed: Grants from Gilead, Intercept, Genfit, Pliant, Novo Nordisk, CymaBay; Advisory board for Mallinckrodt, Pleiogenix; Consultant for Gilead, Pioneering Medicine VII, Inc; Stock held in Intercept, Pleiogenix

Khalili: grants to her institution from Gilead Sciences Inc and Intercept Pharmaceuticals and has served as consultant for Gilead Sciences Inc

Parikh: Institutional grant support from Genentech, Exelixis, Exact Sciences, Glycotest, Bayer; Consulting for Eisai, Genentech, Freenome, Exact Sciences

Sharpton: Consulting for Ionis

Diehl: Institutional grant support from Boerhinger-Ingelheim, Madrigal, Novo Nordisk, Novartis, Celgene, Poxel, Enyo, TARGET-NASH, Genfit, Intercept, Galmed, Astra Zeneca, Axcella Health, Hanmi, Viking, NGM, Allergan, Conatus, Terns; Consulting for Allergan, Alderya, Merck, Filcitrine, Sunbio, CASMA, RAPT Therapeutics, Generon, Atria Pharmaceuticals, DILIsym Services

Moylan: Institution grant support from Exact Sciences, GSK; consulted for Boehringer Inghelheim Inc, Novo Nordisk.

Simonetto: Consulted for Mallinckrodt, BioVie and Generon.

Loomba: RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.

References

    1. Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. Jama 2023;329:1589–1602. - PMC - PubMed
    1. Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clinical Gastroenterology and Hepatology 2019. - PMC - PubMed
    1. Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: the importance of multistate models and competing risks analysis. Hepatology 2015;62:292–302. - PubMed
    1. Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. New England Journal of Medicine 2021;385:1559–1569. - PMC - PubMed
    1. Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, et al. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology 2016;150:785–790. - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources